{"id":"W4402259280","doi":"10.1200/jco.24.00110","title":"Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; F. Hoffmann-La Roche; Memorial Sloan-Kettering Cancer Center; Pfizer","keywords":"Medicine; Palbociclib; Tolerability; Internal medicine; Letrozole; Fulvestrant; Oncology; Adverse effect; Metastatic breast cancer; Breast cancer; Cancer; Tamoxifen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001553211,0.0004336466,0.00315039,0.0002753265,0.00009927866,0.00002517621,0.0002296182,0.0002543979,0.0004751467],"category_scores_gemma":[0.001843173,0.0002819943,0.0007544396,0.0003875135,0.0007597042,0.0005462035,0.0000610605,0.001162967,0.000002982394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004522088,"about_ca_system_score_gemma":0.00239171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006981529,"about_ca_topic_score_gemma":0.00003019048,"domain_scores_codex":[0.99443,0.0006583909,0.003365063,0.0005124278,0.0005227006,0.000511438],"domain_scores_gemma":[0.9893695,0.006472346,0.002221039,0.0002158218,0.001194948,0.0005263125],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5114439,0.003305834,0.00009960768,0.0001994223,0.002358499,0.0002433022,0.000688379,0.0000127424,0.02150047,0.000160453,0.001166221,0.4588211],"study_design_scores_gemma":[0.7641835,0.1593511,0.00329298,0.001198073,0.001477531,0.0013904,0.0009212791,0.0002302073,0.01637024,0.001660714,0.04930333,0.0006206948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9709053,0.008563452,0.001697246,0.01326853,0.002427901,0.00214873,0.0008613866,0.00004840988,0.00007901316],"genre_scores_gemma":[0.9676601,0.01202515,0.01516298,0.00150036,0.002928425,0.0001778778,0.0000312714,0.0001110172,0.0004028593],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4582004,"threshold_uncertainty_score":0.9999632,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1142235611372019,"score_gpt":0.4995596041199905,"score_spread":0.3853360429827886,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}